NFKB1 and ovarian carcinoma: However, combination of BZ and Bay 117085 maximizes the potential of both drugs to inhibit the IL-8 expression and reduce ovarian tumor growth in vivo. In ovarian cancer cells in vitro, the IL-8 expression is regulated by IKKβ-mediated recruitment of S536P-p65 NFκB to the IL-8 promoter [27].